Meta-analysis when only the median survival times are known: a comparison with individual patient data results
- PMID: 15736523
- DOI: 10.1017/s0266462305050154
Meta-analysis when only the median survival times are known: a comparison with individual patient data results
Abstract
Background: The hazard ratio (HR) is the most appropriate measure for time to event outcomes such as survival. In systematic reviews, HRs can be calculated either from the raw trial data obtained as part of an individual patient data (IPD) meta-analysis or from the appropriate trial-level summary statistics. However, the information required for the latter are seldom reported in sufficient detail to allow reviewers to calculate HRs. In contrast, the median survival and survival rates at specific time points are frequently presented. We aimed to evaluate retrospectively the performance of meta-analyses using median survival times and survival rates by comparing them with meta-analyses using IPD to calculate HRs.
Methods: IPD from thirteen published meta-analyses (MAs) in cancers with high mortality rates were used. Median survival and survival rates were calculated from the IPD rather than taken from publications so that the same trials, patients, and extended follow-up are used in each analysis.
Results and conclusions: We show that using median survival times or survival rates at a particular point in time are not reasonable surrogate measures for meta-analyses of survival outcomes and that, wherever possible, HRs should be calculated. Individual trial publications reporting on time to event outcomes, therefore, should provide more detailed statistical information, preferably logHRs and their variances, or their estimators.
Similar articles
-
Comparison of aggregate and individual participant data approaches to meta-analysis of randomised trials: An observational study.PLoS Med. 2020 Jan 31;17(1):e1003019. doi: 10.1371/journal.pmed.1003019. eCollection 2020 Jan. PLoS Med. 2020. PMID: 32004320 Free PMC article.
-
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.Clin Trials. 2005;2(3):209-17. doi: 10.1191/1740774505cn087oa. Clin Trials. 2005. PMID: 16279144
-
Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials.Clin Trials. 2009 Feb;6(1):16-27. doi: 10.1177/1740774508100984. Clin Trials. 2009. PMID: 19254930
-
Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis.PLoS One. 2016 May 5;11(5):e0154870. doi: 10.1371/journal.pone.0154870. eCollection 2016. PLoS One. 2016. PMID: 27149107 Free PMC article. Review.
-
Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.J Clin Oncol. 2016 May 20;34(15):1813-9. doi: 10.1200/JCO.2015.64.2488. Epub 2016 Feb 16. J Clin Oncol. 2016. PMID: 26884584 Review.
Cited by
-
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?Br J Cancer. 2013 Jan 15;108(1):64-71. doi: 10.1038/bjc.2012.504. Br J Cancer. 2013. PMID: 23321511 Free PMC article.
-
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.J Clin Oncol. 2015 Nov 10;33(32):3817-25. doi: 10.1200/JCO.2015.61.5997. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304871 Free PMC article. Review.
-
A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?Evid Based Preclin Med. 2014 Dec;1(1):e00006. doi: 10.1002/ebm2.6. Epub 2015 Jan 20. Evid Based Preclin Med. 2014. PMID: 27668084 Free PMC article. Review.
-
Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial.BMC Med Res Methodol. 2010 Jun 10;10:54. doi: 10.1186/1471-2288-10-54. BMC Med Res Methodol. 2010. PMID: 20537177 Free PMC article.
-
Methodology to standardize heterogeneous statistical data presentations for combining time-to-event oncologic outcomes.PLoS One. 2022 Feb 24;17(2):e0263661. doi: 10.1371/journal.pone.0263661. eCollection 2022. PLoS One. 2022. PMID: 35202406 Free PMC article.